ImmuCell CorpNASDAQ:ICCC
- LAST PRICE8.6000
- TODAY'S CHANGE (%)-0.0900 (-1.0357%)
- Bid / Lots7.5300/ 2
- Ask / Lots8.9900/ 3
- Open / Previous Close8.5100 / 8.6900
- Day Range
- 52 Week Range
- Volume1,930
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ICCC |
|---|---|---|
| 09:32 ET | 157 | 8.51 |
| 01:15 ET | 100 | 8.32 |
| 01:30 ET | 100 | 8.5 |
| 02:44 ET | 100 | 8.74 |
| 02:58 ET | 200 | 8.355 |
| 03:12 ET | 128 | 8.2679 |
| 03:59 ET | 151 | 8.6 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmuCell Corp | 66.6M | 61.0x | --- |
Lipocine Inc | 70.8M | -93.6x | --- |
Harpoon Therapeutics Inc | 62.2M | -0.8x | --- |
Solid Biosciences Inc | 65.0M | -0.8x | --- |
Codiak BioSciences, Inc. | 58.0M | -1.6x | --- |
Mediwound Ltd | 59.3M | -3.5x | --- |
Company Information
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
Contact Information
- Headquarters
- 56 Evergreen DrPORTLAND, ME, United States 04103-1066
- Phone
- 207-878-2770
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- David Tomsche
- President, Chief Executive Officer, Treasurer, Secretary, Director
- Michael Brigham
- Vice President - Sales and Marketing, Director
- Bobbi Brockmann
- Vice President - Manufacturing Operations
- Elizabeth Williams
- Independent Director
- Gloria Basse
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $66.6M |
|---|---|
Revenue (TTM) | $21.1M |
Shares Outstanding | 7.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $0.14 |
Book Value | $4.21 |
P/E Ratio | 61.0x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | 18.7x |
Operating Margin | 6.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
